Mineralys Therapeutics Announced Target-htn Successfully Met Its Primary Endpoint; Key Secondary Endpoint Results Demonstrated A Change In Diastolic Aobp Of -7.1 Mmhg With 50mg
Portfolio Pulse from Charles Gross
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) announced that its Target-HTN Phase 2 trial of lorundrostat, a drug for hypertension and chronic kidney disease, successfully met its primary endpoint. The trial demonstrated a significant change in systolic automated office BP with lorundrostat 50mg and 100mg doses versus placebo. The results were presented at the 2023 American Heart Association Hypertension Scientific Sessions and published in the Journal of the American Medical Association.
September 10, 2023 | 2:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mineralys Therapeutics' successful trial results for lorundrostat could potentially boost the company's stock in the short term as it indicates progress in the company's drug development pipeline.
Successful clinical trial results are typically viewed positively by investors as they indicate progress in a company's drug development pipeline. This could lead to increased investor confidence in Mineralys Therapeutics, potentially driving up the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100